Home   Business   Article

Astex Pharmaceuticals making progress at Barcelona symposium

10:48, 25 October 2024

Astex Pharmaceuticals is set to make five key data presentations at the 36th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics in Barcelona, Spain.

The Astex presentations at the Barcelona symposium, which ends today (25 October) focus on its novel small-molecule CBP/p300 HAT domain inhibitor, ASTX528, in preclinical development, and its Phase II-ready MDM2 antagonist, ASTX295.

Astex Pharmaceuticals building on Cambridge Science Park
Astex Pharmaceuticals building on Cambridge Science Park

Astex, which is based on Cambridge Science Park, is a wholly owned subsidiary of Otsuka Pharmaceutical Co, based in Tokyo, Japan. Founded in 1999, Astex is a leader in innovative drug discovery and development, committed to the fight against cancer and diseases of the central nervous system.

ASTX528 aims to overcome the dose-limiting tolerability issues which have held back previous CBP/p300 HAT domain inhibitors. Astex is interested in discussing the further development of ASTX528 with potential partners.

Dr Harren Jhoti, president and CEO of Astex Pharmaceuticals, with CryoEM facility used in drug discovery. Picture: Astex Pharmaceuticals
Dr Harren Jhoti, president and CEO of Astex Pharmaceuticals, with CryoEM facility used in drug discovery. Picture: Astex Pharmaceuticals

ASTX295 was discovered by Astex in collaboration with the Cancer Research UK Drug Discovery Unit at Newcastle University. The compound was designed to overcome the on-target toxicity seen in the first generation MDM2 antagonist compounds.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies - Learn More